By Nick Stride
Friday 7th March 2003 |
Text too small? |
Wrightson announced its $1.31-a-share stand in the market on Wednesday and finished the day with 15.05%.
It said its Genesis investment was aimed at "providing an impetus" for more collaboration in agricultural biotechnology.
The move is likely to have been approved by its 19.9% shareholder, Fonterra. Both Wrightson and Fonterra subsidiary RD1 have biotech research arms and market observers have speculated Fonterra will eventually take over Wrightson and separate the rural services and biotech divisions.
Genesis' shares have languished below the $1.70 value of its cash reserves of about $36.3 million. They traded at 97c immediately before the Wrightson stand was announced.
British trials of Genesis' Avac eczema treatment showed the drug to be safe and well-tolerated.
No comments yet
Rakon FY2024 Results Announcement Date
WHS - The Warehouse Group FY24 Third Quarter Sales Update
May 10th Morning Report
FY24 Results Announcement Date and Briefing Details
Fonterra appoints permanent CFO
Harapaki wind farm now on track for mid-winter completion
Rabobank picks $8.40 kg/MS forecast milk price for 24/25 dairy season, but warns global dairy price recovery now likely to be slower
Kiwi Property FY24 annual results announcement date
MFB - FY24 Results Announcement Date and Briefing Details
AIA - Announces books closed for retail bond offer